News
A document related to the project entitled Optimal Use of Minimally Invasive Glaucoma Surgery: Recommendation is now available for feedback from all interested stakeholders.
Project
Call for Feedback
Feedback Due By
Optimal Use of Minimally Invasive Glaucoma Surgery: Recommendation
2019-01-22
2019-02-05
Consultation Document
Product Type
Submit ...
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
CADTH has received the following notice(s) of pending drug submission(s).
Brand name
TBC
Generic name
halobetasol propionate and tazarotene
Manufacturer
Bausch Health, Canada Inc.
Indication(s)
Psoriasis, moderate to severe plaque
Project Number
SR0600-000
Call for patient input
2019-01-07
Patient input deadline
2019-02-26
Submit patient input
...
CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website.
Xultophy
Brand name
Generic name
Manufacturer
...
See Pharmaceutical Reviews Update – Issue 4 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:
an upcoming webinar on the CADTH/pCODR clinician input and feedback process
an update on the transition of the Cancer Drug Implementation Advisory Committee work
a reminder about pre-submissio...
